Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBHMY 74 3-Year ROIIC % is 9.04 as of Dec. 2025, which is 46% below its 10-year median of 16.85. GuruFocus rates SBHMY with a GF Score™ of 74/100 and a GF Value™ of $12.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,322 Biotechnology companies, Sino Biopharmaceutical ranks better than 60.82% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sino Biopharmaceutical's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 9.04%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sino Biopharmaceutical's 3-Year ROIIC % or its related term are showing as below:
SBHMY's 3-Year ROIIC % is ranked better than 60.82% of 1322
companies
in the Biotechnology industry
Industry Median: -4.835
vs SBHMY: 9.04
Sino Biopharmaceutical (OTCPK:SBHMY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sino Biopharmaceutical 3-Year ROIIC % Related Terms
Sino Biopharmaceutical 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBHMY vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sino Biopharmaceutical (SBHMY) has a 3-Year ROIIC % of 9.04 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sino Biopharmaceutical and its competitors. This is 46% below median its historical median of 16.85. Over the past decade, Sino Biopharmaceutical's 3-Year ROIIC % has ranged from 0.36 to 1,178.93. According to the industry distribution chart, Sino Biopharmaceutical ranks #518 out of 1322 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Sino Biopharmaceutical's 3-Year ROIIC % too high?
Sino Biopharmaceutical's current 3-Year ROIIC % of 9.04 is 46% below median its 10-year median of 16.85. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 1,178.93. Based on the distribution chart, Sino Biopharmaceutical ranks #518 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #518 out of 1322 companies for 3-Year ROIIC %. This puts Sino Biopharmaceutical in the upper half of its industry. Historically, Sino Biopharmaceutical's own 3-Year ROIIC % has ranged from 0.36 to 1,178.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current 3-Year ROIIC % is 9.04, which is 46% below median its own 10-year median of 16.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBHMY) is currently considered Fairly Valued. The stock's GF Value™ is $12.27, compared to a current price of $12.68 — trading 3.3% above its estimated fair value. The current 3-Year ROIIC % is 9.04, which is 46% below median its 10-year median of 16.85. Sino Biopharmaceutical's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBHMY), the current 3-Year ROIIC % is 9.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBHMY) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of $12.68 is trading 3.3% above its estimated GF Value™ of $12.27.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBHMY:
3-Year ROIIC %: 9.04 (46% below median its 10-year median of 16.85)
GF Value™: $12.27 vs. price of $12.68 (3.3% above fair value)
No single metric tells the full story. See the SBHMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
74GF Score
Get the complete analysis for SBHMY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBHMY has been successfully added to your 
